Streetbeat News

Revenues

MRK

MRNA

MYNZ

PFE

Pharmaceutical companies are focusing on personalized cancer therapies and immunotherapy as new strategies against cancer. Pfizer and Moderna are investing in mRNA technology for cancer treatment, while Merck has shown success with its Keytruda treatment. Mainz Biomed is advancing early cancer detection with its ColoAlert test.

Portfolio Pulse from Upwallstreet

October 10, 2024 | 6:00 pm

NVO

Analysts have provided mixed ratings for Novo Nordisk (NYSE:NVO) over the past three months, with a consistent 'Somewhat Bullish' sentiment. The average 12-month price target is $160, slightly down from the previous $161.43. Novo Nordisk shows strong financial performance with significant revenue growth and high net margins.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:00 pm

LNG

Cheniere Energy (NYSE:LNG) has significantly outperformed the market over the past 15 years, with an annualized return of 32.6%. A $1000 investment in LNG 15 years ago would now be worth $72,011.24. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 6:00 pm

DHI

ITB

LEN

PHM

TMHC

Hurricane Milton's impact on Florida could delay new home construction, affecting major homebuilders like Taylor Morrison, PulteGroup, Lennar, and D.R. Horton. This may lead to increased costs and conservative outlooks in upcoming earnings reports. The iShares U.S. Home Construction ETF, which holds these stocks, could also be impacted.

Portfolio Pulse from Chris Katje

October 10, 2024 | 6:00 pm

AMX

ICARO Media Group has signed a 10-year contract with Claro Brasil, a subsidiary of América Móvil, to enhance Claro's advertising revenue through digital platforms. This partnership involves leveraging RioVerde's communication innovations.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 5:35 pm

PDD

PDD Holdings (NASDAQ:PDD) has significantly outperformed the market over the past 5 years, with an average annual return of 33.18%. A $1000 investment in PDD 5 years ago would now be worth $4,330.62, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 5:30 pm

IDXX

IDEXX Laboratories (NASDAQ:IDXX) has significantly outperformed the market over the past 20 years, achieving an average annual return of 12.15%. A $100 investment in IDXX 20 years ago would be worth approximately $979.31 today, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 5:30 pm

SPY

Despite a stronger-than-expected September CPI report, the market narrative of disinflation and potential interest rate cuts in November remains unchanged. The CPI rose by 2.4% year-over-year, slightly above expectations, while core inflation ticked up to 3.3%. The labor market saw a rise in jobless claims, attributed to temporary disruptions. Fed's Goolsbee downplayed the inflation uptick, emphasizing the broader trend of disinflation. Economists have mixed reactions, with some highlighting temporary factors affecting data. The S&P 500 index, tracked by SPDR S&P 500 ETF Trust (SPY), traded flat.

Portfolio Pulse from Piero Cingari

October 10, 2024 | 5:26 pm

ARKF

ARKW

ROKU

JP Morgan analyst Cory A Carpenter has raised estimates for Roku, Inc. due to strong ad trends and political spending, increasing the price target to $92 with an Overweight rating. The analyst expects strong Platform results and anticipates Roku to benefit from the shift to streaming. Investors can gain exposure through ARK ETFs.

Portfolio Pulse from Lekha Gupta

October 10, 2024 | 5:21 pm

SPCE

Virgin Galactic Holdings (NYSE:SPCE) has received mixed analyst ratings over the past three months, with a shift towards more bearish sentiments. Analysts have lowered their price targets, with an average target of $23.8, down 34.25%. The company has shown significant revenue growth but struggles with profitability and debt management.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 5:01 pm